Licensing opportunities

Currently available licensing opportunities are:

Indication: Hormone-resistant prostate cancer
Status: Phase I

Indication: Hormone-sensitive protate cancer
Status: Phase I

Indication: Diagnosis and prognosis of prostate cancer
Status: Development for commercial use planned, currently marketed for research purposes

Indication: Cancer
Status: Preclinical

Please address any interest or request for more information to:

Daniel Böck, Ph.D.
Vice-President, Business Development and Licensing
Tel.: (514) 751-2003 ext. 236
E-mail: dbock@ambrilia.com

+ Fact Sheet (PDF 816 Kb)